Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Conditions
Interventions
Intervention1: Kaba sura Kudineer: 60 ml twice a day- Morning and Night After food for 10 days
Intervention2: Nilavembu Kuidneer: 60 ml twice a day- Morning and Night After food for 10 days
Control In
Sponsors
Government Institute of Medical Sceinces
Central Council for Research in Siddha
Eligibility
Inclusion criteria
Inclusion criteria: 1. Laboratory Confirmed COVID â?? 19 with Mild and Moderate symptoms (as per ICMR Guidelines) with 2:1 Ratio in each group with proper representation of Age group/Sex. 2. Aged 18-65 years 3. Consenting to participate in the study and sign the informed consent
Exclusion criteria
Exclusion criteria: 1. Patients with severe primary respiratory disease or other pathogenic microbial pneumonia 2. Patient with Uncontrolled DM (>= 350 mgs Fasting Sugar) SevereHT(180/120 mmHg as per JNC 8 Guidelines), Chronic BA(>= 5 years Based on Clinical History), Renal Dysfunction (Known CKD >= 5 years eGFR Stage >= 3 as per NKA guidelines) 3. Pregnant and Lactating mothers 4. Patients with other systemic malignant diseases such as malignant tumors, mental illnesses, which the researchers consider unsuitable for participation in the study 5. People who have history of allergic to Siddha medicine or intolerant to taking medication 6. Patients participating in other COVID-19 clinical trials
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Reduction in Viral load of SARS-CoV-2 at the end of treatment 2.Time taken to convert Patient from symptomatic to Asymptomatic based on Reduction in clinical symptoms like fever, cough and breathlessness 3.Effect of drugs inflammatory markers (IL6,) at the end of treatment. 4.Reduction in use of Intensive Supportive Care Timepoint: 10 Days | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Reduction in incidence of complications (ARDS, other systematic complications) 2.Reduction in hospital stay time. 3.Differenciation in Laboratory markers (Hematological& Bio â?? Chemical Markers) 4.Adverse events/effects Siddha-based measurements 5.Siddha Udaliyal assessment by using YI Tool Timepoint: 10 Days | — |
Countries
India
Contacts
Public ContactDr ANURAG SRIVASTAVA
Government Institute of Medical Sceinces,
Outcome results
None listed